AIDS vaccine nears, twice-yearly antiretroviral drug reaches 100% effectiveness

New achievement Scientific research. Fighting AIDS It has already accumulated several years of study, analysis, successes and a lot of headaches. However, now the results injectable drugs against him HIV They are promising. Preliminary analysis of the phase 3 study GOAL 1 indicates that lenacapavir shows 100% effectiveness in preventing infection in women at high risk.

Medical information portal, Medscapeclaims that an independent data monitoring committee is recommending that Gilead Sciences, the company testing this use of the drug, end the blinded phase and move to a study open to all participants.

Mupali DasGilead Sciences’ executive director of clinical development, points out that in all these years of research, “there has not been another phase 3 study of PrEP that has not seen a single case of infection.”

In the study, two procedures are evaluated and compared with a third, previously used procedure. On the one hand, administration twice a year Lenacapavir subcutaneously for pre-exposure prophylaxis.On the other hand, daily oral administration Descovy in women and girls aged 16 to 25. Both treatments are also compared with the effectiveness of daily oral administration of the drug. Truvada.

No infections were detected in the lenacapavir cohort of over 2,000 women. On the other hand, the HIV incidence rate in the Descovy group was 2.02 per 100 person-years, while in the Truvada group it was 1.69 per 100 person-years.

Three drugs were found to be safe and well tolerated by subjects, but we will have to wait a little longer to see the preliminary data.

This is not a discovery as such, since lenacapavir is already used in adult patients with HIV. It is an antiretroviral drug that belongs to a class of drugs called capsid inhibitors. It blocks the protein shell of HIV and interferes with various key stages of the virus’s life cycle.

The report HIV/AIDS surveillance in Europe 2022, published jointly by the World Health Organization (WHO) Regional Office for Europe and the European Centre for Disease Prevention and Control (ECDC), shows a 30% increase in the number of HIV diagnoses reported in Europe (EU/EEA), while AIDS cases persist and deaths related to the disease are declining again.

Follow us on our channel in WhatsApp and don’t miss the latest news and all the news from the site anten3noticias.com